AML SoC

Phase 1

Johnson & Johnson

AML SoC is one of 6 therapeutic programs targeting Hematologic Neoplasms. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hematologic NeoplasmsRecruiting

Hematologic NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

8 competitors in Hematologic Neoplasms

#DrugCompanyPhaseTrials

Cellcept

Roche

Preclinical

1 2

Fludara

Sanofi

Preclinical

1 3

Busulfex

Akero Therapeutics

Preclinical

1 4

Rapamune

PPrism Pharmaceuticals

Preclinical

1 5

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 6

AML SoC

Johnson & Johnson

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

Phase 1Recruiting

Hematologic Neoplasms

NCT07572006

Clinical

Trials by Indication[1]

Hematologic Neoplasms1 trial

A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT07572006·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AML SoC. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for AML SoC. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Johnson & Johnson

AML SoC

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

Hematologic Neoplasms1 trial

References

Drug Info

Quick Facts

Related News